Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Immune thrombocytopenia (ITP) is an autoimmune disorder in which a combination of
defective platelet production and enhanced clearance leads to thrombocytopenia. The …

Background: Patients with immune thrombocytopenia (ITP) are at risk of bleeding and,
paradoxically, thromboembolic events (TEEs), irrespective of thrombocytopenia. The risk of …

免疫性血小板减少症(immunethrombocytopenia, ITP) 是一种常见的自身免疫性出血性疾病,
表现为外周血血小板计数减低. 针对ITP 的经典初始治疗方案仍为糖皮质激素 …

Background Thrombopoietin receptor agonists are frequently used in treating immune
thrombocytopenia (ITP) owing to high response rates and good tolerability. ITP is associated …

Patients with immune thrombocytopenia (ITP) are at increased risk for bleeding and are
paradoxically at increased risk for thrombosis. Many patients with ITP have underlying …

There are limited data on the impact of severe acute respiratory syndrome corona virus 2
infection in patients previously diagnosed with primary immune thrombocytopenia (ITP) on …

Thrombopoietin receptor agonists (TPO‐RAs) stimulate platelet production, which might
restore immunological tolerance in primary immune thrombocytopenia (ITP). The iROM …

Despite the predisposition to bleeding, patients with immune thrombocytopenia (ITP) may
also have an increased risk of arterial and venous thrombosis, which can contribute to …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by
isolated thrombocytopenia and a haemorrhagic risk. Thrombopoietin receptor agonists (TPO …